Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK1903 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK1903 |
| 2 | PLACEBO_COMPARATOR | Placebo to MK1903 |
| Name | Type | Description |
|---|---|---|
| MK1903 | DRUG | Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period. |
| Comparator: Placebo | DRUG | Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period. |
Inclusion Criteria: * Participant is not on a statin or other lipid-modifying therapy * Low or moderate risk participant * Male participants, and female participants not of reproductive potential Exclusion Criteria: * Female participant of reproductive potential * Participant is pregnant, breastf...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
MK1903 is an investigational small molecule being developed for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is being studied in patients with dyslipidemia as part of a clinical development program.
MK1903 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with dyslipidemia.
MK1903 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness for treating dyslipidemia.
MK1903 has been studied in a Phase 2 clinical trial with the identifier NCT00847197, titled "A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)." This trial enrolled 191 participants and has been completed.
MK1903 is a distinct investigational compound developed by Merck & Company, Inc. No alternative names for MK1903 have been reported in the context of its clinical development for dyslipidemia.